Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity

Diabetes

Volumn 49, Issue 8, 2000, Pages 1374-1380

  Alessi, M C ^a   Bastelica, D ^a   Morange, P ^a   Berthet, B ^a   Leduc, I ^a   Verdier, M ^a   Geel, O ^a   Juhan Vague, I ^a  

^a Laboratoire d'Hématologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MALE; MORBID OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033853610     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.8.1374     Document Type: Article

References (46)

1. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
2. Association of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction: The PRIME Study: Prospective Epidemiological Study of Myocardial Infarction
3. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
4. Fibrinolytic factor and the risk of myocardial infarction of sudden death in patients with angina pectoris
5. Increased fibrin turnover and high PAI activity as predictors of ischemic events in atherosclerotic patients
6. Increased plasma plasminogen activator inhibitor 1 levels: A possible link between insulin resistance and atherothrombosis
7. Regulation of fibrinolysis in the development of atherothrombosis: Role of adipose tissue
8. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease
9. Abdominal obesity
10. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women
11. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity
12. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension
13. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women
14. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice
15. Enhanced expression of PAI-1 in visceral fat: Possible contribution to vascular disease in obesity
16. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat and accumulation and vascular disease
17. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
18. Smad4/DPC4 and Smad3 mediate transforming growth factor-β (TGF-β) signaling through direct binding to a novel TGF-β-responsive element in the human plasminogen activator inhibitor-1 promoter
19. Extracellular matrix-related genes in kidney after ischemic injury: Potential role for TGF-β in repair
20. Tumor necrosis factor-α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1
21. Elevated expression of transforming growth factor-β in adipose tissue from obese mice
22. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: A potential pathogenetic link between obesity and cardiovascular disease
23. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level
24. Glucorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue
25. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody, based on enzyme-linked immunosorbant assay
26. Molecular cloning
27. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
28. Expression of plasminogen activator inhibitor-1 human adipose tissue: A role for TNF-α?
29. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-α and lipopolysaccharide
30. Tumor necrosis factor-α: A key component of the obesity-diabetes link
31. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance
32. Elevated serum TNF-α level is a link between endothelial dysfunction and insulin resistance in normotensive obese patients
33. Circulating tumor necrosis factor-α concentrations are higher in abdominal versus peripheral obesity
34. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus
35. The expression of tumor necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase
36. Transmembrane tumor necrosis factor (TNF)-α inhibits adipocyte differentiation by selectivity activating TNF receptor 1
37. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo
38. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: Role of obesity and non-insulin-dependent diabetes mellitus
39. Depot-related gene expression in human subcutaneous and omental adipocytes
40. Differences in mRNA expression of the proteins secreted by adipocytes in human subcutaneous and visceral adipose tissues
41. Transforming growth factor type β (TGF-β) and adipogenesis in pigs
42. Transforming growth factor beta inhibits the differentiation of human adipocyte precursor cells in primary culture
43. TGF beta 1 prevents the downregulation of type I procollagen, fibronectin, and TGF beta 1 gene expression associated with 3T3-L1 pre-adipocyte differentiation
44. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM
45. Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes
46. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β